首次持股声明
Ocuphire Pharma(OCUP)02-15 07:35
$Ocuphire Pharma(OCUP)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0000905148-24-000741 Size: 12 KB 网页链接
简介:Ocuphire Pharma, Inc.是一家临床阶段的眼科生物制药公司,致力于开发和商业化用于治疗多种眼疾的疗法。Ocuphire的产品线目前包括针对眼部适应症的两种小分子候选产品。该公司的主要产品候选产品Nyxol眼药水是一种每日一次无防腐剂的甲磺酸酚妥拉明的眼药水配方,一种非选择性的α-1和α-2肾上腺素能拮抗剂,旨在减少瞳孔大小,目前正在开发有几种适应症,包括昏暗的灯光或夜视障碍,药理性散瞳和老花眼。Ocuphire的第二个候选产品APX3330是每天两次的口服片剂,旨在抑制与视网膜和脉络膜血管疾病(例如糖尿病性视网膜病变和糖尿病性黄斑水肿)相关的血管生成和炎症途径。
今开:1.55 | 昨收:1.535 |
最高:1.6 | 最低:1.55 |
涨停价: | 跌停价: |
总市值:39701392 |
Ocuphire Pharma(OCUP)02-15 07:35
$Ocuphire Pharma(OCUP)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0000905148-24-000741 Size: 12 KB 网页链接
Ocuphire Pharma(OCUP)02-15 07:45
$Ocuphire Pharma(OCUP)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-000742 Size: 7 KB 网页链接
Ocuphire Pharma(OCUP)02-17 05:05
$Ocuphire Pharma(OCUP)$ 8-K Current report, items 5.02 and 9.01 Accession Number: 0001140361-24-008352 Act: 34 Size: 371 KB 网页链接
Ocuphire Pharma(OCUP)03-21 04:25
$Ocuphire Pharma(OCUP)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-000991 Size: 5 KB 网页链接
Ocuphire Pharma(OCUP)03-09 06:25
$Ocuphire Pharma(OCUP)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001140361-24-012399 Act: 34 Size: 13 MB 网页链接
Ocuphire Pharma(OCUP)03-26 04:45
$Ocuphire Pharma(OCUP)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-000997 Size: 4 KB 网页链接
Ocuphire Pharma(OCUP)03-26 04:55
$Ocuphire Pharma(OCUP)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-000999 Size: 14 KB 网页链接
Ocuphire Pharma(OCUP)04-16 04:15
$Ocuphire Pharma(OCUP)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-001166 Size: 16 KB 网页链接
Ocuphire Pharma(OCUP)03-08 21:25
$Ocuphire Pharma(OCUP)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001140361-24-012128 Act: 34 Size: 402 KB 网页链接
Ocuphire Pharma(OCUP)03-28 04:35
$Ocuphire Pharma(OCUP)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0001140361-24-015624 Act: 34 Size: 6 MB 网页链接
里程碑milestone2023-09-03 17:45
28/09/2023 ET
Nyxol Eye Drops $Ocuphire Pharma(OCUP)$ $3.92
PDUFA date of September 28, 2023.
网页链接{Ocuphire Pharma Announces Financial Results for Second Quarter 2...查看全文
芯片芯事件2021-12-10 09:21
为人们熟知还要感谢电动汽车率先打响了搭载的第一枪,特别是特斯拉,据说其平均每2辆电动车就需要一片6英寸SiC晶圆;SiC器件市占率高达6成的科锐(Cree)产能几乎被它包了一半。市场调研公司Yole Développement表示在市场增长和设计机会方面,SiC已成为最具活力的技术之一。SiC正在渗透到汽车应用...查看全文
鲜克有终72021-06-30 22:22
$Ocuphire Pharma(OCUP)$ 模拟盘魔咒 卖了涨查看全文
鲜克有终72021-06-30 19:38
鲜克有终72021-06-30 19:33
$Ocuphire Pharma(OCUP)$ 10%减点 买高了查看全文
Ocuphire Pharma(OCUP)宣布,已与FamyGen生命科学公司达成独家许可协议,在美国、欧洲、日本、印度、中国和其他全球市场开发和商业化Nyxol三种适应症。在与Famy单独宣布的交易中,Viatris(VTRS)同意在每次监管批准后将Nyxol商业化。 根据许... 网页链接
$Ocuphire Pharma(OCUP)$ PRE 14A Other preliminary proxy statements Accession Number: 0001140361-24-020836 Act: 34 Size: 3 MB 网页链接
$Ocuphire Pharma(OCUP)$ 8-K Current report, items 5.02 and 9.01 Accession Number: 0001140361-24-020320 Act: 34 Size: 351 KB 网页链接
$Ocuphire Pharma(OCUP)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-001166 Size: 16 KB 网页链接
$Ocuphire Pharma(OCUP)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0001140361-24-015624 Act: 34 Size: 6 MB 网页链接
$Ocuphire Pharma(OCUP)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-000999 Size: 14 KB 网页链接
$Ocuphire Pharma(OCUP)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-000997 Size: 4 KB 网页链接
$Ocuphire Pharma(OCUP)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-000991 Size: 5 KB 网页链接
$Ocuphire Pharma(OCUP)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001140361-24-012399 Act: 34 Size: 13 MB 网页链接
$Ocuphire Pharma(OCUP)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001140361-24-012128 Act: 34 Size: 402 KB 网页链接
$Ocuphire Pharma(OCUP)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001140361-24-008374 Act: 33 Size: 293 KB 网页链接